Literature DB >> 16356442

Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease.

Miriam Vos Louthan1, Shirish Barve, Craig J McClain, Swati Joshi-Barve.   

Abstract

OBJECTIVE: To evaluate the relative concentrations of cytokines in pediatric nonalcoholic fatty liver disease (NAFLD). STUDY
DESIGN: Thirty children were evaluated at a fasting morning visit to a pediatric research unit.
RESULTS: Compared with normal-weight children (n = 12) and children who were overweight (n = 11), children who had presumed NAFLD (elevated Alanine aminotransferase [ALT] with negative work-up) (n = 7) had significantly lower mean serum adiponectin levels (P = .004). Adiponectin negatively correlated with body mass index (r = -0.60, P = .001), insulin (r = -0.74, P < .001), glucose (r = -0.52, P = .004), and ALT (r = -0.53, P = .003). There was no difference between normal-weight, obese, and presumed NAFLD subjects in mean serum tumor necrosis factor alpha and interleukin-6 and -8 concentrations nor in tumor necrosis factor alpha and interleukin-8 and -10 levels in an ex vivo lipopolysaccharide-stimulated system.
CONCLUSIONS: Serum adiponectin is reduced in children with elevated ALT, similar to adults. However, children with presumed NAFLD do not have elevated pro-inflammatory cytokine levels. This suggests that depressed adiponectin plays a more proximal role than elevated levels of circulating pro-inflammatory cytokines in the development of NAFLD in children.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16356442     DOI: 10.1016/j.jpeds.2005.07.030

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  31 in total

Review 1.  Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies.

Authors:  Prasenjit Manna; Sushil K Jain
Journal:  Metab Syndr Relat Disord       Date:  2015-12       Impact factor: 1.894

Review 2.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  Development of type 2 diabetes in children and adolescents.

Authors:  Ram Weiss; Sara E Taksali; Sonia Caprio
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

Review 4.  Inflammation and fibrogenesis in steatohepatitis.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2012-02-07       Impact factor: 7.527

Review 5.  Fatty liver in childhood.

Authors:  Yesim Ozturk; Ozlem Bekem Soylu
Journal:  World J Hepatol       Date:  2014-01-27

6.  Effects of kampo formulas on the progression of hypercholesterolemia and Fatty liver induced by high-cholesterol diet in rats.

Authors:  Weibin Qian; Junichi Hasegawa; Satoshi Tsuno; Yusuke Endo; Akiko Matsuda; Norimasa Miura
Journal:  Yonago Acta Med       Date:  2014-12-26       Impact factor: 1.641

7.  Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.

Authors:  Raika Jamali; Mohsen Razavizade; Abbas Arj; Mohammad Hossein Aarabi
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

8.  Association of adiponectin gene polymorphisms and additional gene-gene interaction with nonalcoholic fatty liver disease in the Chinese Han population.

Authors:  Zhang Wei; Zhu Li-Qun; Huo Xiao-Ling; Qin Jian; Yuan Guo-Yue
Journal:  Hepatol Int       Date:  2016-02-10       Impact factor: 6.047

9.  Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease.

Authors:  Miriam B Vos; Shirish Barve; Swati Joshi-Barve; John D Carew; Peter F Whitington; Craig J McClain
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-10       Impact factor: 2.839

10.  Anthropometric and metabolic characteristics in children with clinically diagnosed nonalcoholic fatty liver disease.

Authors:  Diana R Mager; Simon Ling; Eve A Roberts
Journal:  Paediatr Child Health       Date:  2008-02       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.